Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes: Whitehall II Prospective Cohort Study

OBJECTIVE: Although interleukin-1 receptor antagonist (IL-1Ra) treatment is associated with improved β-cell function and glycemic control in patients with type 2 diabetes, its role in the development of type 2 diabetes remains unclear. We used repeated measurements to characterize IL-1Ra trajectorie...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Carstensen, Maren, Herder, Christian, Kivimäki, Mika, Jokela, Markus, Roden, Michael, Shipley, Martin J., Witte, Daniel R., Brunner, Eric J., Tabák, Adam G.
Formato: Artigo
Idioma:Inglês
Publicado: American Diabetes Association 2010
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2857902/
https://ncbi.nlm.nih.gov/pubmed/20185814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db09-1199
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares